Soc. Generale Put 50 BMY 20.09.20.../ DE000SV6QT22 /
2024-06-11 9:47:19 PM | Chg.-0.050 | Bid9:58:31 PM | Ask9:58:31 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.710EUR | -6.58% | 0.710 Bid Size: 15,000 |
0.720 Ask Size: 15,000 |
Bristol Myers Squibb... | 50.00 USD | 2024-09-20 | Put |
GlobeNewswire
5:52 PM
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
2:00 PM
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
GlobeNewswire
06-10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
05-31
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire
05-30
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
05-23
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
05-23
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
05-14
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Immunocore reports first quarter financial results and provides a business update
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-02
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...